array:22 [
  "pii" => "S1699258X20300267"
  "issn" => "1699258X"
  "doi" => "10.1016/j.reuma.2019.12.006"
  "estado" => "S300"
  "fechaPublicacion" => "2021-10-01"
  "aid" => "1402"
  "copyrightAnyo" => "2020"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "cor"
  "cita" => "Reumatol Clin. 2021;17:490"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1699258X20300280"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2020.02.004"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "1404"
    "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Reumatol Clin. 2021;17:489-90"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>"
      "titulo" => "Variante at&#237;pica PFAPA-<span class="elsevierStyleItalic">like</span> de la fiebre mediterr&#225;nea familiar asociada a psoriasis"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "489"
          "paginaFinal" => "490"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Atypical familial mediterranean fever with PFAPA-Like symptoms and psoriasis"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Felipe Blasco, &#193;ngel Garc&#237;a A, Mar&#237;a Dolores Martos, Sandra Mu&#241;oz"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Felipe"
              "apellidos" => "Blasco"
            ]
            1 => array:2 [
              "nombre" => "&#193;ngel"
              "apellidos" => "Garc&#237;a A"
            ]
            2 => array:2 [
              "nombre" => "Mar&#237;a Dolores"
              "apellidos" => "Martos"
            ]
            3 => array:2 [
              "nombre" => "Sandra"
              "apellidos" => "Mu&#241;oz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2173574320301404"
        "doi" => "10.1016/j.reumae.2020.02.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574320301404?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20300280?idApp=UINPBA00004M"
    "url" => "/1699258X/0000001700000008/v1_202109290644/S1699258X20300280/v1_202109290644/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1699258X20301893"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2020.07.005"
    "estado" => "S300"
    "fechaPublicacion" => "2021-10-01"
    "aid" => "1455"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and Sociedad Espa&#241;ola de Reumatolog&#237;a y Colegio Mexicano de Reumatolog&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Reumatol Clin. 2021;17:485-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Reumatolog&#237;a Cl&#237;nica en im&#225;genes</span>"
      "titulo" => "Osteolisis generalizada en un paciente con s&#237;ndrome de Gorham-Stout"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "485"
          "paginaFinal" => "488"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Massive Osteolysis in a Patient with Gorham-Stout Syndrome"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figura 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 2388
              "Ancho" => 2167
              "Tamanyo" => 393716
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Im&#225;genes de RM donde se visualizan m&#250;ltiples aplastamientos vertebrales con hipercifosis secundaria&#44; en el plano sagital de la columna cervical&#44; dorsal y lumbar potenciadas en T1 &#40;A&#41;&#44; TT2 &#40;B&#41; y STIR &#40;C&#41;&#46; M&#250;ltiples lesiones que se comportan hipointensas en T1 e hiperintensas en TT2-STIR con distribuci&#243;n difusa&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Irene Mar&#237;a L&#243;pez Garc&#237;a, Mar&#237;a Teresa Lorenzo Dom&#237;nguez, Ana Mar&#237;a Fern&#225;ndez Mart&#237;nez, Mar&#237;a Teresa Cuesta Marcos"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Irene Mar&#237;a"
              "apellidos" => "L&#243;pez Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "Mar&#237;a Teresa"
              "apellidos" => "Lorenzo Dom&#237;nguez"
            ]
            2 => array:2 [
              "nombre" => "Ana Mar&#237;a"
              "apellidos" => "Fern&#225;ndez Mart&#237;nez"
            ]
            3 => array:2 [
              "nombre" => "Mar&#237;a Teresa"
              "apellidos" => "Cuesta Marcos"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S2173574321000617"
        "doi" => "10.1016/j.reumae.2020.07.006"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321000617?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20301893?idApp=UINPBA00004M"
    "url" => "/1699258X/0000001700000008/v1_202109290644/S1699258X20301893/v1_202109290644/es/main.assets"
  ]
  "en" => array:12 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Systemic sclerosis related interstitial lung disease&#58; What is the recommended treatment&#63;"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Sr&#46; Editor</span>&#58;"
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "490"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Metin I&#351;&#305;k, Murat Kara"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Metin"
            "apellidos" => "I&#351;&#305;k"
            "email" => array:1 [
              0 => "metin1721978@yahoo.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Murat"
            "apellidos" => "Kara"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Internal Medicine and Rheumatology&#44; &#214;zel 100&#46; Y&#305;l Hospital&#44; &#199;ukurambar&#44; Muhsin Yaz&#305;c&#305;o&#287;lu Caddesi No&#58; 54&#44; &#199;ankaya&#44; Ankara&#44; Turkey"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Physical Medicine and Rehabilitation&#44; Hacettepe University Hospital&#44; S&#305;hhiye&#44; Ankara&#44; Turkey"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Enfermedad pulmonar intersticial relacionada con la esclerosis sist&#233;mica&#58; &#191;cu&#225;l es el tratamiento recomendado&#63;"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We have read the article by Sobolewski et al&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a> with great interest and we sincerely congratulate them for highlighting the current developments in the management of systemic sclerosis &#40;SSc&#41;&#46; Although they wanted to gather the newest data about the aetiology&#44; pathophysiology and management&#44; the part regarding the management of SSc related interstitial lung disease &#40;SSc-ILD&#41; has some clerical error&#46; Firstly&#44; they specified that patients with SSc-ILD have stable or slowly progressive disease and only 25&#8211;30&#37; of them need immunosuppressive treatment&#46; This statement creates an impression that ILD in SSc is not a serious complication&#46; However&#44; in the previous part of the same manuscript&#44; it is stated that SSc-ILD is one of the major causes of morbidity and mortality and we know that SSc-ILD is not a benign complication of the disease&#46; Secondly&#44; they reported that mycophenolate mofetil &#40;MMF&#41; is the preferred first line agent for the treatment of SSc-ILD&#46; On the other hand&#44; in the following paragraph&#44; it is written that intravenous cyclophosphamide &#40;CYC&#41; is the recommended first line therapy for SSc-ILD and MMF is a good alternative treatment&#46; In this regard&#44; European League Against Rheumatism &#40;EULAR&#41; also recommends CYC for SSc-ILD in the first line&#44; but not MMF&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In conclusion&#44; as complications in SSc is still characterized by a severe course and high risk of early death&#44; the importance and severity of ILD in SSc patients should be highlighted and the recommended first line treatment for SSc-ILD should be clarified&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:2 [
            0 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic sclerosis &#8211; multidisciplinary disease&#58; clinical features and treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Sobolewski"
                            1 => "M&#46; Ma&#347;li&#324;ska"
                            2 => "M&#46; Wieczorek"
                            3 => "Z&#46; &#321;agun"
                            4 => "A&#46; Malewska"
                            5 => "M&#46; Roszkiewicz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5114/reum.2019.87619"
                      "Revista" => array:6 [
                        "tituloSerie" => "Reumatologia"
                        "fecha" => "2019"
                        "volumen" => "57"
                        "paginaInicial" => "221"
                        "paginaFinal" => "233"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31548749"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update of EULAR recommendations for the treatment of systemic sclerosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "O&#46; Kowal-Bielecka"
                            1 => "J&#46; Fransen"
                            2 => "J&#46; Avouac"
                            3 => "M&#46; Becker"
                            4 => "A&#46; Kulak"
                            5 => "Y&#46; Allanore"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2016-209909"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "1327"
                        "paginaFinal" => "1339"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27941129"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/1699258X/0000001700000008/v1_202109290644/S1699258X20300267/v1_202109290644/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "17506"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Cartas al editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/1699258X/0000001700000008/v1_202109290644/S1699258X20300267/v1_202109290644/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20300267?idApp=UINPBA00004M"
]
Compartir
Información de la revista
Vol. 17. Núm. 8.
Páginas 490 (octubre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 17. Núm. 8.
Páginas 490 (octubre 2021)
Letter to the Editor
Acceso a texto completo
Systemic sclerosis related interstitial lung disease: What is the recommended treatment?
Enfermedad pulmonar intersticial relacionada con la esclerosis sistémica: ¿cuál es el tratamiento recomendado?
Visitas
1929
Metin Işıka,
Autor para correspondencia
metin1721978@yahoo.com

Corresponding author.
, Murat Karab
a Internal Medicine and Rheumatology, Özel 100. Yıl Hospital, Çukurambar, Muhsin Yazıcıoğlu Caddesi No: 54, Çankaya, Ankara, Turkey
b Physical Medicine and Rehabilitation, Hacettepe University Hospital, Sıhhiye, Ankara, Turkey
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
Sr. Editor:

We have read the article by Sobolewski et al.1 with great interest and we sincerely congratulate them for highlighting the current developments in the management of systemic sclerosis (SSc). Although they wanted to gather the newest data about the aetiology, pathophysiology and management, the part regarding the management of SSc related interstitial lung disease (SSc-ILD) has some clerical error. Firstly, they specified that patients with SSc-ILD have stable or slowly progressive disease and only 25–30% of them need immunosuppressive treatment. This statement creates an impression that ILD in SSc is not a serious complication. However, in the previous part of the same manuscript, it is stated that SSc-ILD is one of the major causes of morbidity and mortality and we know that SSc-ILD is not a benign complication of the disease. Secondly, they reported that mycophenolate mofetil (MMF) is the preferred first line agent for the treatment of SSc-ILD. On the other hand, in the following paragraph, it is written that intravenous cyclophosphamide (CYC) is the recommended first line therapy for SSc-ILD and MMF is a good alternative treatment. In this regard, European League Against Rheumatism (EULAR) also recommends CYC for SSc-ILD in the first line, but not MMF.2

In conclusion, as complications in SSc is still characterized by a severe course and high risk of early death, the importance and severity of ILD in SSc patients should be highlighted and the recommended first line treatment for SSc-ILD should be clarified.

References
[1]
P. Sobolewski, M. Maślińska, M. Wieczorek, Z. Łagun, A. Malewska, M. Roszkiewicz, et al.
Systemic sclerosis – multidisciplinary disease: clinical features and treatment.
Reumatologia, 57 (2019), pp. 221-233
[2]
O. Kowal-Bielecka, J. Fransen, J. Avouac, M. Becker, A. Kulak, Y. Allanore, et al.
Update of EULAR recommendations for the treatment of systemic sclerosis.
Ann Rheum Dis, 76 (2017), pp. 1327-1339
Descargar PDF
Idiomas
Reumatología Clínica
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?